Dr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company works with researchers and physicians across Europe to expand patient access to cell therapy. This thought leadership series has been paid and developed by Kite, a Gilead… Read More »Collaboration is key to advancing cell therapy research
In the latest episode of the podcast pharmaphorum’s website editor Catherine Longworth speaks with Dr Darrin Disley, who’s the CEO of Mogrify. The UK biotechnology company is aiming to transform the development of cell therapies using a systematic direct cell conversion & maintenance platform powered by… Read More »Big data and cell therapy development: the pharmaphorum podcast
Cellino Biotech CEO and Co-founder Dr. Nabiha Saklayen talked about the formation of the company and its goal to make stem cell therapies accessible for patients.
UK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that will be used to take its personalised T cell therapy for lung and skin cancers through proof-of-concept trials. The new funding will also be used to advance… Read More »Cancer Research UK spinout Achilles raises $175.5m in IPO
With high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. There is a crucial need to progress candidates from bench to bedside. With that in mind, I am delighted to share the official agenda and speaker faculty… Read More »9th PREDiCT: Tumor Models Cell Therapy Summit
Instil Bio, one of several companies developing tumor-infiltrating lymphocytes, will use its IPO cash to advance its clinical testing plans. Meanwhile, Finch Therapeutics and Gain Therapeutics also priced IPOs to fund clinical trials.
Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy for diabetes. VX-880 (formerly known as STx-02) derives from Vertex’… Read More »FDA fast tracks type 1 diabetes cell therapy from Vertex
Lymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill and Director of Operations and External Affairs Stephen Scowcroft believe it is essential to champion the patient voice in cell therapy. This thought leadership series has been… Read More »Lymphoma Action – championing the patient voice in cell therapy
The pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival in patients with non-small cell lung cancer (NSCLC), sending the biotech’s share price skywards. Interim data from a phase 2 trial of Heat’s off-the-shelf cell therapy with… Read More »Heat Bio’s shares ignite on Opdivo combination data in NSCLC
Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma. The green light comes too late for holders of the contingent value right (CVR) BMS offered as… Read More »BMS finally gets FDA OK for liso-cel, sets $410k launch price
Sana Biotechnology is turning new science into novel medicines intended to overcome limitations of current cell therapies. After going from stealth to IPO in two years, it’s now planning to bring multiple programs into clinical testing in 2022.
Cellino Closes $16M Seed Financing led by The Engine and Khosla Ventures to Automate and Scale Stem Cell Manufacture
What You Should Know: – Cellino, a Cambridge, MA-based personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the closing of a $16M Seed financing round. The round was co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC.… Read More »Cellino Closes $16M Seed Financing led by The Engine and Khosla Ventures to Automate and Scale Stem Cell Manufacture
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in… Read More »Gene editing: beyond the hype
Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch of cell therapy products for solid tumours and blood cancers. The partnership covers up to five oncology targets identified by OBT using its discovery platform, and the… Read More »Oxford BioTherapeutics to research cell therapies for Gilead’s Kite
Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team culture makes it work This thought leadership series has been paid and developed by Kite,… Read More »Why cell therapy manufacture is a team sport
Johnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel) to the FDA, in hot pursuit of Bristol-Myers Squibb’s delayed rival therapy. Cilta-cel – which targets B-cell maturation antigen (BCMA) – has been submitted as a treatment… Read More »Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA
Catamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its off-the-shelf natural killer (NK) cell therapies for cancer through early-stage development. The Cambridge, Massachusetts-based biotech is the latest player in the emerging field of chimeric antigen receptor… Read More »Catamaran joins the CAR-NK fleet, raising $42m in first round
Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million). The French pharma is buying Kiadis for 5.45 euros per share in cash, an offer price representing a premium of… Read More »Sanofi to acquire Kiadis and NK cell tech for $353 million
Bayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US biotech Asklepios BioPharmaceutical, also known as AskBio. AskBio’s portfolio includes pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases.… Read More »Bayer buys cell & gene therapy firm AskBio for $4 billion
Check out new developments from healthcare startups including Bind, ChromaCode and more.
The findings may make it possible to identify a subset of patients who experience poorer outcomes or more serious side effects, especially neurotoxicity.
The company hopes to use the money to bring its T-cell antigen coupler cell therapy technology – currently in preclinical development – into human clinical trials. German drugmaker Bayer’s venture capital arm led the round.
Achieving Standardization & Operational Excellence in Vein-to-Vein Supply As an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment, cell therapies pose unique supply chain challenges. From temperature and time sensitivity, to patient-facing delivery and… Read More »Patient-to-Patient Supply for Cell Immunotherapies Summit
Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond The $4.9 billion acquisition of Forty Seven by Gilead is an example of the explosive excitement and investment into macrophage-directed therapies, utilizing CD47 checkpoint blockades, repolarization… Read More »2nd Macrophage-directed Therapies Summit
Shares in Netherlands biotech Kiadis rose sharply on the news that it would start developing a natural killer (NK) cell therapy for COVID-19, but later lost most of the gains on what looks like profit-taking. Kiadis has joined forces with five Dutch biomedical groups on… Read More »Kiadis shares yo-yo on cell therapy trial for COVID-19
The company said the study of Kymriah in follicular lymphoma met its primary endpoint, though it did not disclose the trial data. It plans to submit approval applications to the FDA and EMA next year.
Cell and gene therapies offer some of the most groundbreaking advancements in patient care the pharma industry has ever seen. However, to fully realise the potential of these innovative therapies, integration across the supply chain is critical – particularly with reimbursement and logistics. As of… Read More »Preparing for an influx of cell and gene therapy approvals
The companies’ resubmission of their application Wednesday seeking approval for idecabtagene vicleucel was in line with the timeline they provided in May, when the FDA sent a refuse-to-file letter in response to their initial submission.
The agency approved Tecartus, previously developed under the name KTE-X19, as the first CAR-T therapy for mantle cell lymphoma. The company had previously won approval for another CAR-T, Yescarta, in 2017, for diffuse large B-cell lymphoma.
The patient, who had been enrolled in the Phase I study at the higher dose level of UCARTCS1A, suffered a cardiac arrest, the causes of which are under investigation, the company said.
With the success of first vaccine to reach phase I clinical trial and turning out to be safe, well-tolerated, and capable of generating an immune response against the virus in humans, a lot of hope has been created with this vaccine. However, the research is… Read More »Cell Therapy: A Potential Treatment for COVID-19?